What is the current stock price of Maze Therapeutics, Inc. (MAZE)?

As of the latest market data, Maze Therapeutics, Inc. (MAZE) is trading at $26.69. The stock has seen a loss of -4.27% today.

Does Maze Therapeutics, Inc. (MAZE) pay a dividend?

Based on current data, Maze Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Maze Therapeutics, Inc.?

The current market capitalization of Maze Therapeutics, Inc. (MAZE) is approximately unavailable.

MAZE

Maze Therapeutics, Inc.·Healthcare

26.69

4.268%(−1.19)

Market Closed

27.20

1.911%(+0.51)

After Hours

Last Updated: — ET

52W L: $7.1652W H: $53.65

MAZE NEWS

fool.com

6d ago

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026. This disposition represented 100% of Harold Bernstein's direct Common Stock holdings, reducing his direct ownership of Common Stock to zero.

Company Profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

125

IPO Date

2025-01-31

Beta

5.16

Websitewww.mazetx.com↗

MAZE

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829